Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms
Fibrosis is a physiological response to organ injury and is characterized by the excessive deposition of connective tissue components in an organ, which results in the disruption of physiological architecture and organ remodeling, ultimately leading to organ failure and death. Fibrosis in the lung,...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2021/6673525 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563257315950592 |
|---|---|
| author | Maoyan Wu Huiwen Xu Jingyu Liu Xiaozhen Tan Shengrong Wan Man Guo Yang Long Yong Xu |
| author_facet | Maoyan Wu Huiwen Xu Jingyu Liu Xiaozhen Tan Shengrong Wan Man Guo Yang Long Yong Xu |
| author_sort | Maoyan Wu |
| collection | DOAJ |
| description | Fibrosis is a physiological response to organ injury and is characterized by the excessive deposition of connective tissue components in an organ, which results in the disruption of physiological architecture and organ remodeling, ultimately leading to organ failure and death. Fibrosis in the lung, kidney, and liver accounts for a substantial proportion of the global burden of disability and mortality. To date, there are no effective therapeutic strategies for controlling fibrosis. A class of metabolically targeted chemicals, such as adenosine monophosphate-activated protein kinase (AMPK) activators and peroxisome proliferator-activated receptor (PPAR) agonists, shows strong potential in fighting fibrosis. Metformin, which is a potent AMPK activator and is the only recommended first-line drug for the treatment of type 2 diabetes, has emerged as a promising method of fibrosis reduction or reversion. In this review, we first summarize the key experimental and clinical studies that have specifically investigated the effects of metformin on organ fibrosis. Then, we discuss the mechanisms involved in mediating the antifibrotic effects of metformin in depth. |
| format | Article |
| id | doaj-art-f3422900bdbc417395441b3050b7d070 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-f3422900bdbc417395441b3050b7d0702025-02-03T01:20:44ZengWileyJournal of Diabetes Research2314-67452314-67532021-01-01202110.1155/2021/66735256673525Metformin and Fibrosis: A Review of Existing Evidence and MechanismsMaoyan Wu0Huiwen Xu1Jingyu Liu2Xiaozhen Tan3Shengrong Wan4Man Guo5Yang Long6Yong Xu7Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, ChinaDepartment of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, ChinaSouthwest Medical University, Luzhou, Sichuan, 646000, ChinaCardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, Sichuan, 646000, ChinaDepartment of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, ChinaCardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, Sichuan, 646000, ChinaDepartment of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, ChinaDepartment of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, ChinaFibrosis is a physiological response to organ injury and is characterized by the excessive deposition of connective tissue components in an organ, which results in the disruption of physiological architecture and organ remodeling, ultimately leading to organ failure and death. Fibrosis in the lung, kidney, and liver accounts for a substantial proportion of the global burden of disability and mortality. To date, there are no effective therapeutic strategies for controlling fibrosis. A class of metabolically targeted chemicals, such as adenosine monophosphate-activated protein kinase (AMPK) activators and peroxisome proliferator-activated receptor (PPAR) agonists, shows strong potential in fighting fibrosis. Metformin, which is a potent AMPK activator and is the only recommended first-line drug for the treatment of type 2 diabetes, has emerged as a promising method of fibrosis reduction or reversion. In this review, we first summarize the key experimental and clinical studies that have specifically investigated the effects of metformin on organ fibrosis. Then, we discuss the mechanisms involved in mediating the antifibrotic effects of metformin in depth.http://dx.doi.org/10.1155/2021/6673525 |
| spellingShingle | Maoyan Wu Huiwen Xu Jingyu Liu Xiaozhen Tan Shengrong Wan Man Guo Yang Long Yong Xu Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms Journal of Diabetes Research |
| title | Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms |
| title_full | Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms |
| title_fullStr | Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms |
| title_full_unstemmed | Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms |
| title_short | Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms |
| title_sort | metformin and fibrosis a review of existing evidence and mechanisms |
| url | http://dx.doi.org/10.1155/2021/6673525 |
| work_keys_str_mv | AT maoyanwu metforminandfibrosisareviewofexistingevidenceandmechanisms AT huiwenxu metforminandfibrosisareviewofexistingevidenceandmechanisms AT jingyuliu metforminandfibrosisareviewofexistingevidenceandmechanisms AT xiaozhentan metforminandfibrosisareviewofexistingevidenceandmechanisms AT shengrongwan metforminandfibrosisareviewofexistingevidenceandmechanisms AT manguo metforminandfibrosisareviewofexistingevidenceandmechanisms AT yanglong metforminandfibrosisareviewofexistingevidenceandmechanisms AT yongxu metforminandfibrosisareviewofexistingevidenceandmechanisms |